Pre-made Simtuzumab benchmark antibody ( Whole mAb, anti-LOXL2 therapeutic antibody, Anti-LOR/LOR2/WS9-14 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-522

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-522 Category Tag

Product Details

Pre-Made Simtuzumab biosimilar, Whole mAb, Anti-LOXL2 Antibody: Anti-LOR/LOR2/WS9-14 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.

Products Name (INN Index)

Pre-Made Simtuzumab biosimilar, Whole mAb, Anti-LOXL2 Antibody: Anti-LOR/LOR2/WS9-14 therapeutic antibody

INN Name

Simtuzumab

Target

LOXL2

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2012

Companies

Arresto Biosciences,Gilead Sciences

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Colorectal cancer,Hepatic fibrosis,Idiopathic pulmonary fibrosis,Liver cirrhosis,Myelofibrosis,Non-alcoholic steatohepatitis,Pancreatic cancer,Primary sclerosing cholangitis

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

LOXL2

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide